Can Fite Biopharma Stock Market Value
| CANF Stock | USD 4.18 0.14 3.47% |
| Symbol | Can |
Can Biotechnology industry sustain growth momentum? Does Can have expansion opportunities? Factors like these will boost the valuation of Can Fite. Projected growth potential of Can fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Can Fite demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding Can Fite Biopharma requires distinguishing between market price and book value, where the latter reflects Can's accounting equity. The concept of intrinsic value - what Can Fite's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Can Fite's price substantially above or below its fundamental value.
It's important to distinguish between Can Fite's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Can Fite should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Can Fite's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Can Fite 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Can Fite's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Can Fite.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Can Fite on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Can Fite Biopharma or generate 0.0% return on investment in Can Fite over 90 days. Can Fite is related to or competes with Kazia Therapeutics, CNS Pharmaceuticals, Clearmind Medicine, Soligenix, GRI Bio, Oragenics, and Silo Pharma. Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for th... More
Can Fite Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Can Fite's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Can Fite Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 38.42 | |||
| Value At Risk | (8.59) | |||
| Potential Upside | 10.4 |
Can Fite Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Can Fite's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Can Fite's standard deviation. In reality, there are many statistical measures that can use Can Fite historical prices to predict the future Can Fite's volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.80) | |||
| Total Risk Alpha | (1.42) | |||
| Treynor Ratio | 0.541 |
Can Fite February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | 0.551 | |||
| Mean Deviation | 4.89 | |||
| Coefficient Of Variation | (809.48) | |||
| Standard Deviation | 7.12 | |||
| Variance | 50.73 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.80) | |||
| Total Risk Alpha | (1.42) | |||
| Treynor Ratio | 0.541 | |||
| Maximum Drawdown | 38.42 | |||
| Value At Risk | (8.59) | |||
| Potential Upside | 10.4 | |||
| Skewness | (0.11) | |||
| Kurtosis | 2.59 |
Can Fite Biopharma Backtested Returns
Can Fite Biopharma secures Sharpe Ratio (or Efficiency) of -0.12, which signifies that the company had a -0.12 % return per unit of risk over the last 3 months. Can Fite Biopharma exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Can Fite's Mean Deviation of 4.89, risk adjusted performance of (0.08), and Standard Deviation of 7.12 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -1.64, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Can Fite are expected to decrease by larger amounts. On the other hand, during market turmoil, Can Fite is expected to outperform it. At this point, Can Fite Biopharma has a negative expected return of -0.89%. Please make sure to confirm Can Fite's maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if Can Fite Biopharma performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.06 |
Virtually no predictability
Can Fite Biopharma has virtually no predictability. Overlapping area represents the amount of predictability between Can Fite time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Can Fite Biopharma price movement. The serial correlation of 0.06 indicates that barely 6.0% of current Can Fite price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.06 | |
| Spearman Rank Test | -0.1 | |
| Residual Average | 0.0 | |
| Price Variance | 0.09 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Can Fite Correlation, Can Fite Volatility and Can Fite Performance module to complement your research on Can Fite. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Can Fite technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.